Screener
EBIT at other companies
Other financials
Where this comes from
Calculated from Corvus Pharmaceuticals’s reported figures.
Plus components not separately reported this period.
The source filing: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026. Open the filing →
- Filed
- May 7, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-057100
FAQ
- What is Corvus Pharmaceuticals's EBIT?
- Corvus Pharmaceuticals (CRVS) reported EBIT of -$14.88M in Q1 2026.
- How has Corvus Pharmaceuticals's EBIT changed year-over-year?
- Corvus Pharmaceuticals's EBIT decreased by 49.9% year-over-year, from -$9.92M to -$14.88M.
- What is the long-term trend for Corvus Pharmaceuticals's EBIT?
- Over 4 years (2021 to 2025), Corvus Pharmaceuticals's EBIT has grown at a 2.7% compound annual growth rate (CAGR), from -$38.63M to -$42.97M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.
Ask your AI about Corvus Pharmaceuticals's ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude